How India Exports Rosuvastatin to the World

Rosuvastatin calcium, a statin medication used to manage dyslipidemia, has been a significant component of the U.S. pharmaceutical market. The FDA approved the first generic version of rosuvastatin in April 2016, marking the end of AstraZeneca's patent exclusivity. Since then, numerous Abbreviated New Drug Applications (ANDAs) have been approved, reflecting a competitive generic landscape. As of March 2026, the FDA's Orange Book lists multiple approved ANDAs for rosuvastatin calcium tablets, indicating sustained market interest and availability.

The United States remains the primary destination for Indian exports of rosuvastatin, accounting for 42.3% of total exports. This substantial market share underscores the importance of compliance with FDA regulations, including adherence to Current Good Manufacturing Practices (cGMP) and timely reporting of adverse events. Indian exporters must ensure rigorous quality control and regulatory compliance to maintain and expand their presence in the U.S. market.

In the European Union, rosuvastatin received marketing authorization through a Mutual Recognition Procedure initiated in December 2002, with the Netherlands serving as the reference member state. The European Medicines Agency (EMA) has since overseen the regulation of rosuvastatin, ensuring compliance with EU standards. Similarly, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for rosuvastatin, aligning with EMA guidelines.

Manufacturers exporting rosuvastatin to the EU and UK must comply with Good Manufacturing Practice (GMP) requirements as stipulated by the EMA and MHRA. This includes regular inspections and adherence to quality standards to ensure the safety and efficacy of the product.

Rosuvastatin is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025. This inclusion highlights its significance in managing cardiovascular diseases globally. The WHO Model List serves as a guide for countries to develop their national essential medicines lists, promoting access to vital medications.

Regarding pharmacopoeial standards, rosuvastatin is listed in major compendia, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards ensures the quality and consistency of rosuvastatin products across different markets.

In India, rosuvastatin is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) regulates its price to ensure affordability. As of March 2026, the ceiling price for rosuvastatin 10 mg tablets is set at ₹10.50 per tablet, as per the latest NPPA notification.

For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products. While rosuvastatin is generally permitted for export, exporters must ensure compliance with DGFT regulations and obtain necessary clearances to facilitate smooth international trade.

The primary patent for rosuvastatin (RE37,314) expired in 2016, leading to the approval of generic versions by the FDA in April 2016. This expiration has resulted in increased generic competition, benefiting consumers through reduced prices and improved accessibility.

In April 2025, the WHO launched the National Essential Medicines Lists (nEMLs) repository, a centralized digital platform compiling 150 national essential medicines lists. This initiative aims to enhance access to critical healthcare data, supporting policymakers and healthcare professionals in decision-making processes. (who.int)

In September 2025, the WHO published the 24th edition of the Model List of Essential Medicines, reaffirming the inclusion of rosuvastatin. This underscores its continued importance in global health strategies for managing cardiovascular diseases. (who.int)

These developments reflect ongoing efforts by international health organizations to standardize and improve access to essential medicines, including rosuvastatin, thereby influencing global trade and regulatory landscapes.

India's pharmaceutical industry, renowned as the "pharmacy of the world," heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) production. Approximately 70% of APIs and KSMs are imported from China, underscoring a significant supply chain vulnerability. This dependency is particularly concerning for drugs like Rosuvastatin, where the synthesis process is contingent upon the availability of specific KSMs.

The COVID-19 pandemic in early 2020 exposed the fragility of this reliance. Disruptions in Chinese manufacturing led to shortages of critical APIs, including those for widely used medications. In response, the Indian government initiated the Production Linked Incentive (PLI) scheme in February 2021, allocating ₹6,940 crore to bolster domestic production of 53 identified APIs and KSMs. Despite these efforts, as of December 2023, imports from China continued to grow, indicating that the PLI scheme's impact is gradual and the industry still faces challenges in achieving self-reliance.

Our proprietary trade data from 2022 to 2026 reveals that the top five Indian exporters of Rosuvastatin account for 56.3% of total exports, with STRIDES PHARMA SCIENCE LIMITED leading at a 17.0% share. This concentration indicates a moderate risk, as disruptions affecting these key suppliers could significantly impact global Rosuvastatin availability.

The PLI scheme aims to mitigate such risks by promoting diversification and enhancing domestic manufacturing capabilities. However, the scheme's full impact is yet to be realized, and the industry continues to grapple with challenges in reducing dependency on a limited number of suppliers.

Geopolitical tensions and shipping disruptions pose additional risks to the Rosuvastatin supply chain. Incidents in critical maritime routes, such as the Red Sea and the Strait of Hormuz, have historically led to delays and increased shipping costs. Furthermore, escalating U.S.-China tensions could result in trade restrictions or tariffs, potentially affecting the availability and pricing of essential KSMs sourced from China.

Regulatory bodies like the FDA and EMA have issued shortage alerts for various medications in recent years, highlighting the impact of supply chain vulnerabilities. While Rosuvastatin has not been specifically mentioned, the interconnected nature of pharmaceutical supply chains means that disruptions in one area can have cascading effects.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a limited number of sources.

• Enhance Domestic Production: Leverage government incentives like the PLI scheme to invest in local manufacturing of APIs and KSMs.

• Strengthen Supply Chain Monitoring: Implement robust tracking systems to identify and address potential disruptions proactively.

• Develop Strategic Reserves: Maintain buffer stocks of critical APIs and KSMs to mitigate the impact of sudden supply interruptions.

• Foster International Collaboration: Work with global partners to establish alternative supply routes and share best practices in supply chain resilience.

RISK_LEVEL: MEDIUM